Management of Treatment-Experienced HIV-Infected Patients

  • Author: Eric S. Daar, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 7/16/19 (What's New)

Summary

  • CCR5 antagonists currently approved for use in patients without detectable CXCR4-using virus[Fätkenheuer 2008; Gulick 2008]
  • If previous tropism testing results show no CXCR4-tropic virus, repeat testing should be considered before initiating therapy with CCR5 antagonists
  • A subset of people who experience maraviroc failure without detectable CXCR4-using virus actually have true resistance to drug[Jubb 2009]

Action required

Keywords: Management of Treatment-Experienced Patients, Resistance Testing, Tropism

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.